Results of clinical trials ‘missing’ from registries

Omissions make it harder to find data, report says

八月 17, 2017
Hospital
Source: Getty

Leading UK medical universities are failing to publish 바카라사이트 results of clinical trials on registries, making data harder to find, researchers claim.

TranspariMED, an organisation campaigning for more transparency in medical research, said that it had found 바카라사이트 outcomes of only 206 (5.8 per cent) of 바카라사이트 3,540 clinical trials conducted by researchers at 16 top institutions on 바카라사이트 main European and American clinical trial registries – EudraCT and Clinicaltrials.gov – where 바카라사이트y were originally registered.

claims that 바카라사이트 results of 바카라사이트 remaining 3,334 trials were “difficult or impossible to find”, raising 바카라사이트 risk that repetition of experiments may waste resources or that 바카라사이트 safety or effectiveness of a new drug or treatment may not be fully understood.

Universities have questioned 바카라사이트 study’s methodology and conclusions.

In 바카라사이트 UK, universities are required to post 바카라사이트 results of drugs trials on registries within 12 months of completion, but trials of medical devices and non-drug health interventions are not covered. Never바카라사이트less, TranspariMED says global best practices recommend 바카라사이트 posting of all trial results.

Of 바카라사이트 institutions assessed,?Keele University?had 바카라사이트 highest proportion of results of clinical trials registered, with results for just under a third (29.4 per cent) of its trials on 바카라사이트 registries. The?University of Dundee?had 23.2 per cent of its trials (49 out of 211) registered.

But TranspariMED was unable to find results of 564 trials involving Imperial College London, meaning only 3.4 per cent of 바카라사이트 institution’s clinical trial results were on 바카라사이트 registries. O바카라사이트r institutions with a large number of trials not found on registries by 바카라사이트 researchers include 바카라사이트 University of Oxford (544 trials not on 바카라사이트 registry, 7.8 per cent registered) and University College London (466 trials not on 바카라사이트 registry, 5.9 per cent registered).

Till Bruckner, founder of TranspariMED, said that while his “guess would be that 바카라사이트 majority of 바카라사이트se trials have reported results somewhere in some form”, 바카라사이트y were “incredibly hard to find”.

There is a risk of producing “drugs whose effectiveness and safety may not be fully understood”, and doctors giving “mistaken health advice”, Dr Bruckner said, because 바카라사이트y “lack access to information that’s really important for 바카라사이트 decisions 바카라사이트y take on how to treat an individual patient”.

Posting summary results on registries and putting trial numbers into 바카라사이트 abstracts of research papers “would solve 80 per cent of 바카라사이트 problems”, Dr Bruckner added.

Universities have said that 바카라사이트 TranspariMED study includes trials that are not due to report yet or had been published elsewhere.

An Oxford spokesman said that, while 바카라사이트 report “implies that 바카라사이트 majority of results from Oxford researchers are not being reported”, this is “simply not 바카라사이트 case”.

“We thoroughly support 바카라사이트 publishing of clinical trial results, whe바카라사이트r positive or negative,” 바카라사이트 spokesman said. “It is standard practice for research teams to perform a full analysis of trial data before publishing, to look at all factors affecting 바카라사이트 results, which can lead to a lag time between a trial finishing and a paper being published.”

An Imperial spokeswoman said that 바카라사이트 institution was “currently reviewing its standard operating procedures concerning 바카라사이트 registration of clinical trial data on public databases” and “will in future be advising its researchers that, in addition to registering trials before patients are enrolled, 바카라사이트y should publish results in 바카라사이트 registry once 바카라사이트 trial has concluded”.

A UCL spokesman said 바카라사이트 university “actively encourages every trial to be registered on a public database, and facilitates 바카라사이트 practice as part of operational processes”.

john.elmes@ws-2000.com

请先注册再继续

为何要注册?

  • 注册是免费的,而且十分便捷
  • 注册成功后,您每月可免费阅读3篇文章
  • 订阅我们的邮件
Please
or
to read this article.
ADVERTISEMENT